Thymosin Alpha-1 vs VIP (Vasoactive Intestinal Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Thymosin Alpha-1
Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a crucial role in immune system modulation. It is approved in over 35 countries for various conditions including hepatitis B and C.
Full details →VIP (Vasoactive Intestinal Peptide)
VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.
Full details →Side-by-Side Comparison
| Aspect | Thymosin Alpha-1 | VIP (Vasoactive Intestinal Peptide) |
|---|---|---|
| Dose Range | 1.6 mg–3.2 mg | 100 mcg–200 mcg |
| Frequency | Less than daily | 1x daily |
| Cycle Length | 4–12 weeks | 2–8 weeks |
| Route | subcutaneous | intranasal |
| Mechanism | Enhances T-cell function and maturation, stimulates dendritic cell activity, and modulates cytokine production. Promotes the differentiation of stem cells into mature T lymphocytes. | Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects. |
| Typical Dosage | Clinical dosing typically ranges from 1.6mg to 6.4mg administered subcutaneously 2-3 times weekly. Research protocols may vary. | Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition. |
| Administration | Subcutaneous injection. Often used in cycles or as part of comprehensive immune support protocols. | Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light. |
| Side Effects | Generally well-tolerated. Rare side effects include injection site reactions, mild flu-like symptoms, and temporary fatigue. | May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses. |
| Best For |
Key Differences
Unique to Thymosin Alpha-1:
Unique to VIP (Vasoactive Intestinal Peptide):
Key Studies
Thymosin Alpha-1
- Aging and Thymosin Alpha-1.
International journal of molecular sciences, 2025
- Phenotypic drug discovery: a case for thymosin alpha-1.
Frontiers in medicine, 2024
- The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.
Inflammopharmacology, 2023
VIP (Vasoactive Intestinal Peptide)
- Distribution of vasoactive intestinal peptide (VIP) immunoreactivity in the rat pallial and subpallial amygdala and colocalization with γ-aminobutyric acid (GABA).
Anatomical record (Hoboken, N.J. : 2007), 2024
- Increased Vasoactive Intestinal Peptide (VIP) in polycystic ovary syndrome patients undergoing IVF.
Frontiers in endocrinology, 2024
- Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis.
Frontiers in pharmacology, 2021
Ready to Learn More?
Looking for trusted sources?